MediGene to Hold Conference Call to Discuss Excellent Clinical Results Of the Polyphenon(R) E Ointment European Phase 3 Trial MARTINSRIED, Germany and SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- The German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announced today, that CEO Dr. Peter Heinrich, and Vice President of Clinical Research & Development, Dr. Axel Mescheder, will discuss clinical results of the Polyphenon(R) E Ointment European Phase 3 trial via a conference call scheduled for 8:30 AM EST April 1, 2004. In a press release earlier today, MediGene announced the excellent Phase 3 results on Polyphenon(R) E. For the full press release, please visit http://www.medigene.com/. Conference Call Info: Participants may dial-in by calling 1-888-243-3996 from the United States and Canada or by calling 1-973-409-9257 internationally. In the event that you are unable to participate in the conference call, a replay of the call will be available for one week by calling 1-877-519-4471 (PIN# 4660786) from the United States and Canada or by calling 1-973-341-3080 internationally. About MediGene: With locations in Martinsried, Germany and San Diego, USA, MediGene AG is focused on researching and developing novel approaches for the treatment of various tumor diseases. The Company has the most mature drug development pipeline in the German biotech industry and possesses innovative platform technologies. MediGene has become the first German biotechcompany with an approved drug, with Eligard(R) (previously known as Leuprogel(R)) for the treatment of prostate cancer now on the verge of market launch. A second drug candidate, Polyphenon(R) E Ointment for the treatment of genital warts, completed a Phase 2/3 study in 2001 with highly promising results. Patient recovery rate was 59%, with a three month relapse rate for those patients of just 12.5%. At present, MediGene is carrying through a Phase 3 clinical study in Europe and America, involving almost 1,000 patients. MediGene expects an annual sales potential of at least 100 MM ? for Polyphenon(R) E Ointment. This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. DATASOURCE: MediGene AG CONTACT: Julia Hofmann, Public Relations, +49-89-85-65-3324, or Dr. Michael Nettersheim, Investor Relations, +49-89-85-65-2946, both of MediGene AG, , Fax, +49-89-85-65-2920 Web site: http://www.medigene.com/

Copyright